Aktienanalyse zu Arrowhead Pharmaceuticals, Inc. (ARWR)ARWRArrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arrowhead Pharmaceuticals Inc is a good buy right now due to its recent positive clinical trial results, which showed triglyceride reductions of 79% and 81%, and a strong financial position with $1.6 billion in cash and investments. The current price of $84.91 is significantly lower than the analyst price target of $120, indicating a potential upside of 41%. However, the main risk is the negative earnings per share (EPS) of -1.36 reported for the last quarter, which highlights ongoing financial challenges.